The Imugene Limited (ASX: IMU) share price is shooting higher on Monday morning.
At the time of writing, Imugene shares are up 4.54% to 23 cents.
Whatâs driving Imugene shares higher?
Investors are bidding up the Imugene share price after the company advised it received a DIR licence for its novel cancer-killing virus, CF33-hNIS (Vaxinia).
Granted by the Australian Governmentâs Office of the Gene Technology Regulator (OGTR), the licence allows Imugene to expand its Vaxinia phase 1 clinical trial within Australia.
A DIR is a dealing involving the intentional release of genetically modified organisms (GMOs). The regulator sets out the conditions under which such dealings must be undertaken when a DIR licence is approved.
In May 2022, Imugeneâs Vaxinia trial commenced across the US, delivering a low dose of CF33-hNIS to patients with metastatic or advanced solid tumours and who had at least two prior lines of standard of care treatment.
The oncolytic virus, developed by City of Hope, has shown to shrink solid tumours in preclinical laboratory and animal trials.
These tumours include colon, lung, breast, ovarian and pancreatic cancers.
City of Hope is one of the largest cancer research and treatment organizations in the United States.
The study aims to recruit 100 patients across approximately 10 sites in the United States and Australia.
The trial is anticipated to run for approximately 24 months and will be funded from Imugeneâs existing cash reserves.
Commenting on being granted the licence, Imugene managing director and CEO, Leslie Chong said:
Weâre pleased to see this regulatory hurdle cleared on schedule which will allow the smooth progression of our VAXINIA Phase 1 trial as planned.
Imugene share price summary
Despite todayâs gain, it has been a disappointing 12 months for Imugene investors, with the companyâs share price falling more than 50%.
Imugene presides a market capitalisation of approximately $1.29 billion.
The post Imugene share price leaps 5% on trial news appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now
See The 5 Stocks
*Returns as of September 1 2022
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- Why did the Imugene share price have such a lousy end to the week?
- Imugene share price sinks on $80 million cap raise
- Why is the Imugene share price on ice today?
- Imugene share price leaps 5% on trial news
- What’s going on with the Imugene share price on Thursday?
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/Qu1CX4U
Leave a Reply